Bell Investment Advisors’s Summit Therapeutics SMMT Stock Holding History

Bell Investment Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$481	Hold	33	–	–	﹤0.01%	1739
2026 Q1	$626	Buy	+33	New	+$534	﹤0.01%	1668
2025 Q4	–	Sell	-136	Closed	-$2.81K	–	1936
2025 Q3	$2.81K	Hold	136	–	–	﹤0.01%	1194
2025 Q2	$2.9K	Buy	136 +22	+19%	+$502	﹤0.01%	1209
2025 Q1	$2.2K	Buy	114 +48	+73%	+$963	﹤0.01%	1275
2024 Q4	$1.18K	Buy	+66	New	+$1.28K	﹤0.01%	1535

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bell Investment Advisors's SMMT Position: Q2 2026 in Review

Bell Investment Advisors held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 33 shares worth $481. The position accounts for ﹤0.01% of the portfolio, ranked #1739.

Bell Investment Advisors first reported a position in SMMT in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.9K in Q2 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Bell Investment Advisors held 33 shares of Summit Therapeutics worth $481 as of Q2 2026.
Bell Investment Advisors left its Summit Therapeutics share count unchanged in Q2 2026.
Summit Therapeutics made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #1739 holding.
Bell Investment Advisors first reported a position in Summit Therapeutics in Q4 2024 and has held it in 6 quarters since.
Bell Investment Advisors's Summit Therapeutics position peaked at $2.9K in Q2 2025.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.